HASBROUCK HEIGHTS, N.J., Oct. 11, 2018 — Following many shareholder enquiries in recent weeks Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide shareholders with a brief update on its core activities:
- Regulatory Filings for Fexapotide in BPH: The Company is pleased with the progress its regulatory filings for its lead product, Fexapotide Triflutate, are making for BPH (Benign Prostatic Hyperplasia) both in Europe and the United States. The successful financing earlier this summer has allowed the Company to expand its work with top-end regulatory teams on both continents. Consequently, management is very pleased with the level of competence and the overall quality of work going into the filings. Management expects to update its shareholders with regard to timelines for the filings in the near future.
- Quality Control: The Company has augmented its internal quality control activities with an expanded team and a new office located in Orange County, California.
- Prostate Cancer: The Company recently reported very strong and important long-term data from prostate cancer patients that had received treatment with Fexapotide Triflutate (FT) for their diagnosed early-stage prostate cancers. FT’s ability to positively impact the progression of the disease in this patient group went beyond management’s initial expectations for this 146-patient U.S. Phase IIb clinical trial. The Company is now taking steps for the dialogue with regulators regarding the upcoming clinical path for this important indication. The Company will also update its shareholders as these milestones occur.
On another note, the Company is very pleased to also announce that it has recently received official positive rulings from the authorities on 2 different new patent applications (in Europe and in U.S.) which will provide considerable added patent coverages for Nymox’s lead prostate treatment products which are currently in late stages of development for marketing for BPH and prostate cancer. The Company has extensive ongoing patent applications in its patent pipeline.
For more information please contact [email protected] or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on Fexapotide, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2017, and its Quarterly Reports.
For Further Information Contact: Erik Danielsen Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com